



Dr. Noushin Davoudi

Associate Professor of Medical Biotechnology

Biotechnology Research Center

Pasteur Institute of Iran

Papers:

No.	Title	Journal	J. Impact Factor	J. Cite Score	Published	Cited By
1	Leishmaniasis vaccine candidates for development: A global overview	Indian Journal of Medical Research 123(3), pp. 423-438	1.508 Q3	1.06 Q3	2006	127
2	Expression of human tissue plasminogen activator in the trypanosomatid protozoan Leishmania tarentolae	Biotechnology and Applied Biochemistry 48(1), pp. 55-61	1.44 Q4	1.37 Q2	2007	27
3	Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials	Vaccine 23(9), pp. 1170-1177	3.285 Q2	3.19 Q1	2005	26
4	Anti-leishmanial and	Parasitology	2.558	2.46	2012	20

No.	Title	Journal	J. Impact Factor	J. Cite Score	Published	Cited By
	toxicity activities of some selected Iranian medicinal plants	Research 111(5), pp. 2115-2121	Q2	Q1		
5	Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments	Journal of Biomedicine and Biotechnology 2010,108159			2010	14
6	Increased expression of recombinant human tissue plasminogen activator in Leishmania tarentolae	Biotechnology Journal 5(11), pp. 1198-1206	3.507 Q2	3.12 Q2	2010	14
7	Expression of recombinant human coagulation factor VII by the lizard Leishmania expression system	Journal of Biomedicine and Biotechnology 2011,873874			2011	13
8	A p53 codon 72 polymorphism associated with breast cancer in Iranian patients	African Journal of Pharmacy and Pharmacology 5(10), pp. 1278-1281			2011	10
9	VLP production in Leishmania tarentolae: A novel expression system for purification and assembly of HPV16 L1	Protein Expression and Purification 116, pp. 7-11	1.338 Q4	1.42 Q3	2015	7
10	Human tissue plasminogen activator expression in Escherichia coli using cytoplasmic and periplasmic cumulative power	Avicenna Journal of Medical Biotechnology 2(3), pp. 131-136		1.3 Q3	2010	7
11	Cloning and expression of human IFN-γ in Leishmania tarentolae	World Journal of Microbiology and Biotechnology 27(8), pp. 1893-1899	2.1 Q3	2.14 Q2	2011	5

No.	Title	Journal	J. Impact Factor	J. Cite Score	Published	Cited By
12	A Dual Drug Sensitive L. major Induces Protection without Lesion in C57BL/6 Mice	PLoS Neglected Tropical Diseases 8(5),e2785	4.367 Q1	4.36 Q1	2014	5
13	Cloning and expression of truncated form of tissue plasminogen activator in Leishmania tarentolae	Biotechnology Letters 33(3), pp. 503-508	1.846 Q3	1.88 Q2	2011	4
14	Monoclonal antibodies expression improvement in CHO cells by PiggyBac transposition regarding vectors ratios and design	PLoS ONE 12(6),e0179902	2.766 Q1	3.01 Q1	2017	3
15	Gene regulation of pteridine reductase 1 in leishmania promastigotes and amastigotes using a full-length antisense construct	Iranian Journal of Parasitology 8(2), pp. 190-196	1.043 Q4	1.42 Q3	2013	3
16	Identification of the serotypes of bacterial meningitis agents; implication for vaccine usage	Iranian Journal of Microbiology 6(4), pp. 211-218		1.27 Q3	2014	3
17	Introduction of three independent selection markers in Leishmania	Iranian Biomedical Journal 7(1), pp. 13-18		1.92 Q2	2003	3
18	Cytosolic expression of functional Fab fragments in Escherichia coli using a novel combination of dual SUMO expression cassette and EnBase ® cultivation mode	Journal of Applied Microbiology 123(1), pp. 134-144	2.16 Q3	2.41 Q2	2017	3

19	Expression and purification of HCV core and core-E1E2 proteins in different bacterial strains	Iranian Journal of Biotechnology 13(3),e1249, pp. 57-62	0.338 Q4	0.49 Q4	2015	1
20	Comparison of HCV core and CoreE1E2 Virus-Like particles generated by stably transfected leishmania tarentolae for the stimulation of Th1 immune responses in mice	Current Drug Delivery 14(7), pp. 1040-1049	2.078 Q3	1.67 Q2	2017	1
21	Optimizing production of recombinant tissue plasminogen activator in non-pathogenic Leishmania by two genetic constructs	Tehran University Medical Journal 68(11), pp. 629-637		0.21 Q3	2011	0